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Abstract
Background. Non-alcoholic fatty liver disease (NAFLD) is linked to an increased risk of cardiovascular disease. Mean platelet
volume (MPV), a determinant of platelet activation, is an emerging risk factor for atherothrombosis.
Aims. The aim of this study was to investigate the levels of MPV in subjects with NAFLD having no confounding factors for
atherosclerosis such as obesity, diabetes mellitus, and hypertension. In addition, the possible relationship between MPV and
carotid artery intima media thickness (CIMT), a well known marker of subclinical atherosclerosis, was also studied.
Methods. MPV and CIMT levels were measured in 60 biopsy-proven NAFLD subjects and 54 healthy controls. Age and sex
were similar between two groups.
Results. Body mass index and waist circumference levels were higher in the NAFLD group when compared to the controls.
There were no differences between the two groups regarding LDL cholesterol levels, whereas HDL cholesterol levels were
lower in the NAFLD group. MPV and CIMT levels were not different between the two groups. According to the correlation
analyses, CIMT levels were positively correlated to age in patients with NAFLD. However, no signiﬁcant correlation was
found between MPV and CIMT levels.
Conclusions. The results of this study do not show any difference in MPV levels between subjects with NAFLD and controls.
These ﬁnding suggests that in the absence of other metabolic risk factors, MPV might not be involved in the mechanism(s) of
increased cardiovascular risk in NAFLD.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is increas-
ingly diagnosed worldwide and considered to be the
commonest liver disorder in clinical practice. It com-
prises a disease spectrum from variable degrees of
simple steatosis (SS) to non-alcoholic steatohepatitis
(NASH) and cirrhosis. SS is benign, whereas NASH
is characterized by hepatocyte injury, inﬂammation,
and ﬁbrosis which can lead to cirrhosis, liver failure,
and hepatocellular carcinoma (1,2).
NAFLD is strongly associated with insulin
resistance, obesity, hypertension, and dyslipidemia
and is now regarded as the liver manifestation of
the metabolic syndrome (3). Subjects with NAFLD
have a higher prevalence of atherosclerosis, as shown
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ness (CIMT), numbers of atherosclerotic plaques,
and circulating markers of endothelial dysfunc-
tion (4–6). Thus, a number of studies have reported
the increased prevalence of cardiovascular, cerebro-
vascular, and peripheral vascular diseases in subjects
with NAFLD (7,8). Although an indirect association
between NAFLD and cardiovascular disease (CVD)
is reported, a growing body of evidence supports a
direct role for NAFLD in the pathogenesis of athero-
sclerotic CVD (9).
Platelets, whose size mainly depends on the degree
of fragmentation of megakaryocytes, are anucleate
cells (10). It is known that large platelets have a
greater content of granules and can therefore exert
their haemostatic, vasomotor, and pro-inﬂammatory
functions with greater efﬁcacy, so increased platelet
activation is associated with increased platelet vol-
ume (11,12). Platelet activation may also be associ-
ated with microvesicle formation (smaller platelets).
Mean platelet volume (MPV), a determinant of
platelet activation, is an emerging risk factor for
atherothrombosis (13). The increase in MPV may
take place in acute myocardial ischemia (14), acute
myocardial infarction (15), coronary atheroscle-
rosis (16), the presence and the short-term prognosis
of stroke (17) and the long-term risk of stroke (18).
Also, case-control studies have documented signiﬁ-
cant associations of MPV with type 2 diabetes mellitus
(T2DM) (19), pre-diabetes (20), obesity (21), and
other metabolic risk factors (22,23).
The biological mechanisms by which NAFLD
might contribute to accelerated atherosclerosis are
still poorly understood. The main aim of this case
control study was to investigate the association of
NAFLD with MPV levels as an independent risk
factor of atherosclerosis. In addition, the possible
relationship between MPV and CIMT, as well as
being a known marker of subclinical atherosclerosis,
was also investigated. In order to prevent any inter-
ference of confounding factors for inﬂammation or
atherosclerosis, we studied a speciﬁcally selected
group having no additional disorders such as hyper-
tension, diabetes mellitus, or obesity.
Methods
Subjects
A total of 60 male subjects with biopsy-proven
NAFLD referred to the out-patient clinic of the
Department of Gastroenterology, Gulhane School
of Medicine, Ankara, Turkey were enrolled in the
study. Inclusion criteria were: persistently (for at least
6 months) elevated aminotransferases, ultrasono-
graphic presence of hyperechogenic liver without
any other liver or biliary tract disease, liver histology
compatible with a diagnosis of NASH or SS. Exclu-
sion criteria were: a history of alcohol consumption
40 g/wk, as assessed by a detailed interview extended
to family members, obesity (BMI ‡30 kg/m
2), hyper-
tension, positive blood markers of viral, autoimmune,
or celiac disease, abnormal copper metabolism
or thyroid function tests, a diagnosis of overt
diabetes mellitus (fasting blood glucose ‡7 mmol/L
or ‡11.1 mmol/L at 2 hours on a standard oral glucose
load, oral glucose tolerance test), total cholesterol
(TC) ‡6.47 mmol/L, triglycerides (TG) ‡4.52
mmol/L, exposure to occupational hepatotoxins or
drugs known to be steatogenic or to affect glucose and
lipid metabolism. The control group consisted of
54 healthy male subjects, matched for age, with nor-
mal liver enzymes and abdominal ultrasonography.
All participants provided a medical history and under-
went a clinical examination. The weight and height of
the participants were measured with a calibrated scale
after the patients had removed their shoes and any
heavy clothing. Body mass index (BMI) was com-
puted as body weight/(height
2). Waist (narrowest
diameter between xiphoid process and iliac crest)
and hip (widest diameter over greater trochanters)
circumferences to derive waist-to-hip ratio (WHR)
were measured as well.
The study was approved by the local ethics com-
mittee of Gulhane School of Medicine, and all parti-
cipants signed informed consent.
Biochemical measurements
For biochemical analyses, all blood samples were
collected from an antecubital vein, between 08.00
and 09.00 a.m. after an overnight fasting. The sam-
ples were centrifuged for 15 minutes at 4000 rpm,
aliquoted and immediately frozen at 80C for anal-
yses until assayed. All samples were run in the same
batch. Fasting plasma glucose (FPG), TC, TG, and
high-density lipoprotein cholesterol (HDL-C) levels
were measured by the enzymatic colorimetric method
with Olympus AU2700 autoanalyzer using reagents
from Olympus Diagnostics, (GmbH, B). Low-
density lipoprotein cholesterol (LDL-C) was calcu-
lated by Friedewald’s formula (24).
The serum basal insulin level was measured in
duplicate by the electrochemiluminescence method
with Modular Analytics E170 autoanalyzer using
reagents from Roche Diagnostics (Mannheim, Ger-
many). Insulin resistance was calculated by modiﬁed
homeostasis model assessment of insulin resistance
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IR = fasting plasma insulin (mU/mL)  fasting plasma
glucose (mmol/L)/22.5. HOMA-IR was originally
reported by Matthews et al. (25), and this index
has been shown to be well correlated with the results
of the euglycemic–hyperinsulinemic clamp method to
determine insulin resistance (26).
MPV levels were measured in a blood sample
collected in citrate (1:4 v/v) in order to avoid the
platelet swelling induced by EDTA (27). An ABX
Pentra 120 automatic hematology analyzer (Horiba
ABX Diagnostics, Montpellier Cedex, France) was
used for whole blood counts.
Histopathologic analysis
Liver tissue was stained with hematoxylin-eosin, reti-
culin, and Gomori trichrome stains and scored by an
experienced pathologist. All cases showed macrove-
sicular steatosis affecting at least 5% of hepatocytes
and were classiﬁed as steatosis. In addition to stea-
tosis, the minimum criteria for the diagnosis of stea-
tohepatitis included the presence of lobular
inﬂammation and either ballooning cells or perisinu-
soidal/pericellular ﬁbrosis in zone 3 of the hepatic
acinus. All cases were scored using the method
of Brunt (28). Steatosis was graded as follows:
grade 1 (5%–33% of hepatocytes affected); grade
2 (33%–66%); or grade 3 (>66% of hepatocytes
affected). Fibrosis was assessed with the Mason tri-
chrome stain. Other histological features evaluated in
hematoxylin-eosin sections included lobulillar inﬂam-
mation and portal inﬂammation.
CIMT measurement
The assessment of the CIMT was performed by one
experienced radiologist who was blinded to the diag-
nosis of participants. High-resolution B-mode ultra-
sound images were obtained with use of a 7.5-MHz
transducer (Power Vision 8000, Toshiba Shiomoishi-
gami, Otawara-Shi, Japan). The right and left
common carotid artery and the carotid bifurcation-
bulb areas were scanned from multiple planes. Images
were obtained from the far wall of the distal 10 mm of
left and right common carotid arteries at a site free
from any discrete plaque.
Statistical analysis
Results are reported as the mean ± SD and median
(min–max). The Kolmogorov-Smirnov test was used
to determine the distribution characteristics of vari-
ables, and Levene’s test was used to evaluate the
equality of variance. Differences between groups
were tested for signiﬁcance by independent samples
t test and Mann-Whitney U test, as appropriate. The
relationship between variables was analyzed by
Spearman’s rho correlation. Differences and correla-
tions were considered signiﬁcant at P < 0.05.
Results
Table I shows the main characteristics and the labo-
ratory data of the patients and the controls. Age was
similar between the two groups. BMI and WC levels
were higher in the NAFLD group when compared the
controls.
MPV and CIMT levels were not different in the two
groups (Figures 1 and 2). FPG, TC, and TG levels
were higher in the NAFLD group than in the controls.
There were no differences between the two groups
regarding LDL-C, whereas HDL-C levels were lower
in the NAFLD group (Table I).
According to the correlation analyses, CIMT levels
were positively correlated to age in patients with
NAFLD (r = 0.37, P = 0.03). However, no signiﬁcant
correlation was found between MPV and CIMT
levels.
Discussion
This preliminary study has shown that MPV levels are
not different in subjects with NAFLD who have no
confounding factors such as hypertension, diabetes,
and obesity, in comparison with healthy controls. The
abnormalities in glucose and lipid metabolism and
also blood pressure that can potentially affect endo-
thelial function are frequently accompanied by
NAFLD. Therefore, including only subjects free
from any confounding factor is an important feature
of the present investigation.
Insulin resistance, oxidative stress and subsequent
lipid peroxidation, pro-inﬂammatory cytokines, adi-
pokines, and mitochondrial dysfunction are the main
pathogenetic factors in the development of NAFLD.
Furthermore, accumulating evidence supports an
association between NAFLD and metabolic syn-
drome (2,3). Although the data are mainly epidemi-
ological, NAFLD and metabolic syndrome seem to
have common pathophysiological mechanisms with
focus on insulin resistance as a key factor. On the
other hand, the existence of cardiovascular involve-
ment in NAFLD is well established. Accumulation of
abdominal fat seems to be the key factor driving both
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strong risk factor for increased carotid intima media
thickness (30) and reduced endothelial function (31).
However, whether NAFLD is a consequence of or a
contributor to the dysmetabolic cascade that occurs in
insulin resistance and metabolic syndrome is not well
established. Experimental and human studies suggest
that both mechanisms are probably involved. There
Table I. The characteristics of the subjects with non-alcoholic fatty liver disease (NAFLD) and controls.
NAFLD (n = 60) Controls (n = 54) P
Age (years) 31.7 ± 5.6 30.3 ± 5.6 0.17
a
BMI (kg/m
2) 26.7 ± 1.9 23.6 ± 2.1 <0.001
a
WC (cm) 93.8 ± 4.3 86.5 ± 6.1 <0.01
a
FPG (mmol/L) 5.06 ± 0.69 4.52 ± 0.47 <0.001
a
TC (mmol/L) 5.27 ± 1.08 4.73 ± 0.79 <0.005
a
TG (mmol/L) 1.91 (0.25–4.22) 1.22 (0.58–3.28) <0.001
b
HDL (mmol/L) 1.1 ± 0.18 1.25 ± 0.27 0.01
a
LDL (mmol/L) 3.06 (0.62–5.69) 2.74 (1.55–4.42) 0.29
b
ALT (IU/L) 89 (37–207) 16.5 (6–40) <0.01
b
AST (IU/L) 41 (20–148) 20 (11–35) <0.01
b
Insulin (mU/mL) 9.8 (2.1–31.3) 6.7 (3.1–18.5) 0.01
b
HOMA-IR 2.18 (0.34–7.38) 1.46 (0.59–4.06) <0.001
b
MPV (fL) 8.9 ± 1.1 8.8 ± 0.9 0.77
a
CIMT (mm) 0.59 ± 0.11 0.56 ± 0.06 0.23
a
Histology:
Fat score (1/2/3) (%) 60/28/12 - -
Necro-inﬂammation score (0/1/2/3) (%) 10/72/18/0 - -
Fibrosis stage (0/1/2/3/4) (%) 55/40/3/2/0 - -
The data are presented as the mean ± SD or median (minimum–maximum).
aIndependent sample t test.
bMann-Whitney U test.
BMI = body mass index; WC = waist circumference; FPG = fasting plasma glucose; TC = total cholesterol; TG = triglyceride; HDL-C = high-
density lipoprotein-cholesterol; LDL-C = low-density lipoprotein-cholesterol; ALT = alanine aminotransferase; AST = aspartate amino-





















Figure 1. CIMT levels in subjects with NAFLD and controls. There were no differences between two groups according to CIMT levels.
256 G. Kilciler et al.is, as yet, no direct evidence that reducing liver fat is
beneﬁcial for cardiovascular morbidity and mortality,
and a large majority of patients with NAFLD proba-
bly might die of cardiovascular disease before they
develop liver failure. Overall, the current body of
evidence strongly suggests that NAFLD is likely to
be associated with increased CVD risk and raises the
possibility that NAFLD may be not only a marker but
also an early mediator of atherosclerosis (32).
Platelet volume is a marker of platelet function and
activation. It is measured as MPV by clinical hema-
tology analyzers (13). Larger platelets are more
reactive than smaller ones and produce more pro-
thrombotic factors. On the other hand, endothelial
dysfunction favors platelet activation (33). In studies
with T2DM patients and subjects with impaired glu-
cose tolerance, MPV levels were found to be higher
compared to controls, and it is proposed that higher
MPV levels may play a role in the micro- and macro-
vascular complications related to T2DM (19). MPV
levels in patients with obesity were found to be higher
compared to controls, and there was a positive cor-
relation between obesity and MPV levels (21).
Besides, it was shown that weight loss in obese
patients was associated with a reduction in MPV
levels (34). In hypertensive patients, elevated MPV
levels have also been reported (23). Hypercholester-
olemia, another risk factor of atherosclerosis, has
effects on platelet function such as platelet size (mea-
sured as MPV), platelet aggregation, and platelet
activation (35). Consequently, in order to reduce
the effect of metabolic factors, mentioned above,
we designed this study with patients who have no
confounding factors such as hypertension, diabetes,
and obesity. We did not ﬁnd a signiﬁcant difference
regarding the MPV between the two groups. In addi-
tion, there were no relations between MPV and
CIMT levels and other metabolic parameters such
as glucose and lipids. Overall, this ﬁnding suggests
that in the absence of other metabolic risk factors,
MPV per se is not involved in the mechanism(s) of
increased cardiovascular risk in NAFLD.
CIMT is a reliable index of subclinical atheroscle-
rosis, and epidemiologic studies have demonstrated
that there is a signiﬁcant association between CIMT
and CVD (36,37). In a systematic review, including
seven studies with 1427 patients and 2070 controls,
increased CIMT levels were reported in NAFLD
when compared to controls (38). When these studies
were analyzed separately, some of the patients with
NAFLD had metabolic confounders like obesity and
T2DM (39–41). It has been reported that CIMT
levels may be affected by these metabolic risk factors.
So, we think that some of the previous reports regard-
ing the CIMT in NAFLD might be affected by these
metabolic confounders. In addition, the age of the
study participants were older in the above-mentioned
studies, and it is well known that there is a strong and
independent relationship between age and CIMT. In
the present study, we found no differences in CIMT
levels between subjects with NAFLD and controls.
However, there was a signiﬁcant correlation between
age and CIMT in subjects with NAFLD. In light of
these ﬁndings, we suggest that NAFLD is not inde-
pendently associated with carotid atherosclerosis in
people who have no metabolic abnormalities, and age
may be an important determinant for the develop-
ment of atherosclerosis in NAFLD. Thus, our ﬁnd-
ings are consistent with the results of recently
published reports about this issue (42–44).
There are two limitations of the present study.
Firstly, through the sample size and the strict inclusion
criteria, the ﬁndings obtained are not representative for

















Figure 2. MPV levels in subjects with NAFLD and controls. There were no differences between two groups according to MPV levels.
Mean platelet volume and carotid atherosclerosis 257of our study was a requirement to achieve the goals.
Secondly,thoughitissimple, non-invasive,and known
to be correlated well with the clamp test, the HOMA
formulausedtocalculateinsulin sensitivity inthiswork
is only an estimate and cannot be as accurate as the
euglycemic–hyperinsulinemic clamp method.
In conclusion, the results of this preliminary report
do not show any difference in MPV levels between
subjects with NAFLD and controls. These ﬁndings
suggest that in the absence of other metabolic risk
factors MPV might not be involved in the mechanism
(s) of increased cardiovascular risk in NAFLD.
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